吡非尼酮
医学
尿
泌尿科
纤维化
肾
内科学
胃肠病学
肾脏疾病
磁共振成像
肾病科
病理
特发性肺纤维化
作者
Joachim H. Ix,Rebecca Scherzer,Dena E. Rifkin,Meyeon Park,Anna Malkina,Zhen J. Wang,Onur Potok,Afshin Parsa,Michael G. Shlipak
标识
DOI:10.1681/asn.2025cfv4nn85
摘要
Background: Kidney tubule-interstitial fibrosis is highly prognostic for CKD progression. Pirfenidone is FDA approved to treat idiopathic pulmonary fibrosis in humans, and has prevented kidney fibrosis in animal models. Whether pirfenidone prevents kidney fibrosis in humans with CKD is unknown Methods: We conducted a two-site, double blind, randomized clinical trial testing pirfenidone 1335 mg/day vs. matched placebo in 98 participants with CKD. Inclusion required eGFR > 20 and 5 year KFRE risk > 1% at baseline. Key exclusions included ADPKD, liver disease, active smoking, and QTc > 500msec. After a 2-week active run-in, participants were randomized and treated for 12 months. Kidney fibrosis was assessed by apparent diffusion coefficient (ADC) of the kidney cortex by MRI (1° outcome), assessment of 8 urine biomarkers (exploratory outcomes), and albuminuria. Linear mixed models evaluated changes over 12 months by treatment arm. Results: Mean age was 73±13 years, 87% were men, 59% had diabetes, mean eGFR was 36±11 ml/min/1.73m2, and median urine ACR was 145 (IQR 35, 549) mg/g. Characteristics were well balanced at baseline. Ninety-two participants had acceptable baseline MRIs, and 73 (79%) had month 12 MRI. All 98 provided baseline urine biomarker data, and 84 (86%) provided month 12 biomarker data. Seventy-nine percent of participants completed the 12-month study on study medication per protocol. Randomization to pirfenidone was not associated with changes in ADC by MRI over 12 months, urine biomarkers of kidney damage or albuminuria (Table). Conclusion: Treatment with pirfenidone for 12 months did not improve MRI imaging of kidney fibrosis or urine biomarkers of kidney tubule damage in this trial among persons with moderate CKD. Funding: NIDDK Support - NIDDK Support, NIDDK Support
科研通智能强力驱动
Strongly Powered by AbleSci AI